Dr. Stella Vnook discusses how pricing transparency and VBC might have a more positive impact than MFN and other pricing regulations.
Dr. Stella Vnook
Advertisement
Dr. Stella Vnook is chair and acting CEO of Kaida BioPharma.
Articles by Dr. Stella Vnook
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression
2
Regeneron Agrees to Lower Drug Costs for U.S. Patients and Provide Otarmeni for Free
3
Amazon One Medical Launches GLP-1 Management Program
4
Moving Cell and Gene Therapy Towards the Future: Q&A with Maher Masoud
5